Detecting and treating TB go hand in hand. In order to most effectively and responsibly use new drug regimens, diagnostics that can detect drug-resistance are needed. Similarly, enhanced methods of detecting various forms of TB are of reduced value without appropriate treatment. TB Alliance and FIND are collaborating to harmonize development of these new tools.
View Innovation >
TB is a global problem that requires global solutions. The TB Alliance has been working with the International Scientific Exchange Foundation of China (ISEFC) in their effort to launch the Global Health Research & Development Center of China.
View Innovation >
The Open Forum Series engages regulatory authorities around the world to identify and address crucial issues involved in advancing new TB regimens to registration, and ultimately to the people who need them.
View Innovation >
Every dollar donated to the TB Alliance produces $1.60 in impact. The TB Alliance is committed to making its donors' contributions go as far as possible. A network of partners and series of innovative initiatives ensures maximum impact of donor funds, while helping to intensify the fight against TB.
View Innovation >
The CPTR initiative, co-founded in part by the TB Alliance, is working to speed the introduction of impactful, new TB drug regimens.
View Innovation >
The TB Alliance isn’t just developing drugs, but changing the way TB drug development is conducted. New TB multi-drug regimens show promise in offering dramatically faster, simpler, safer, and less toxic therapies that enable global scale-up of treatment, particularly for MDR-TB.
View Innovation >
There are simply not enough high-quality sites that can undertake the sophisticated clinical trials needed to test new TB drugs. The TB Alliance scoured the world to find the most appropriate sites, and shared that information, so that sponsors can advance promising products in the pipeline.
View Innovation >
The TB Alliance is working with the U.S. CDC TB Trials Consortium and the AIDS Clinical Trials Group of the U.S. NIAID, NIH, to identify biomarkers for TB, which can dramatically speed the time and decrease the cost of clinical trials for new TB drugs.
View Innovation >
Partnership is at the foundation of the TB Alliance’s operating model. With this in mind, the TB Alliance collaborates with several Product Development Partnerships (PDPs) to establish cross-PDP partnerships that foster innovation and efficiencies along with the sharing of information and resources.
View Innovation >